Endocrine Abstracts

Context: Metabolic diseases affect millions of people in both developed and transition countries. In addition to genetic inheritance of risk alleles, emerging evidence has shown that these diseases are also linked to lifestyle and inherited epigenetic pattern interactions. The strong link between epigenetics and metabolism may offer attractive clinical applications to counteract and manage the escalating prevalence of metabolic diseases, such as obesity, type 2 diabetes mellit...

Context: Obesity is a global epidemic and an independent risk factor for several metabolic disorders. Emerging evidence suggests a role for epigenetic factors, such as microRNAs (miRNAs), in the development of obesity. MiRNAs are small non-coding RNAs that regulate gene expression. Moreover, circulating miRNAs are potential noninvasive biomarkers because they are stable in body fluids and can be detected using validated techniques, such as quantitative PCR. However, the identi...

Context: Since the exact cause of type 1 diabetes mellitus (T1DM) remains unclear, the detection of novel biomarkers is necessary to complement the information obtained from the presence of autoantibodies together with genetic and environmental risk factors. MicroRNAs (miRNAs) are a class of small noncoding RNA molecules that negatively regulate gene expression. Changes in their expression were described in several pathological conditions, including autoimmune diseases. Circul...

Introduction: Diabetic kidney disease (DKD) is the major cause of end-stage renal disease; however, the pathogenesis of this disease is not fully understood. Currently available therapies are not totally efficacious in the treatment and prognosis of DKD, suggesting that further understanding of the molecular mechanisms underlying the pathogenesis of this disease is necessary to improve its management. Recently, research on microRNAs (miRNAs) has become a hotspot because of the...

Context: Diabetic kidney disease (DKD) is a common microvascular complication that affects approximately 40% of patients with diabetes mellitus (DM). This complication is the leading cause of end-stage renal disease (ESRD) in patients starting renal replacement therapy and is associated with increased cardiovascular mortality. Although a tight glycemic control is able to reduce the development and delay the progression of DKD, current therapies are still not totally effective ...